Literature DB >> 33531485

Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution.

Yang Liu1, Shuai He1,2,3, Xi-Liang Wang4, Wan Peng1, Qiu-Yan Chen1, Dong-Mei Chi1,5, Jie-Rong Chen1,6, Bo-Wei Han1, Guo-Wang Lin1,7, Yi-Qi Li1, Qian-Yu Wang1, Rou-Jun Peng1, Pan-Pan Wei1, Xiang Guo1, Bo Li8,9, Xiaojun Xia1, Hai-Qiang Mai1, Xue-Da Hu4, Zemin Zhang10,11, Yi-Xin Zeng12, Jin-Xin Bei13,14,15.   

Abstract

The heterogeneous nature of tumour microenvironment (TME) underlying diverse treatment responses remains unclear in nasopharyngeal carcinoma (NPC). Here, we profile 176,447 cells from 10 NPC tumour-blood pairs, using single-cell transcriptome coupled with T cell receptor sequencing. Our analyses reveal 53 cell subtypes, including tumour-infiltrating CD8+ T, regulatory T (Treg), and dendritic cells (DCs), as well as malignant cells with different Epstein-Barr virus infection status. Trajectory analyses reveal exhausted CD8+ T and immune-suppressive TNFRSF4+ Treg cells in tumours might derive from peripheral CX3CR1+CD8+ T and naïve Treg cells, respectively. Moreover, we identify immune-regulatory and tolerogenic LAMP3+ DCs. Noteworthily, we observe intensive inter-cell interactions among LAMP3+ DCs, Treg, exhausted CD8+ T, and malignant cells, suggesting potential cross-talks to foster an immune-suppressive niche for the TME. Collectively, our study uncovers the heterogeneity and interacting molecules of the TME in NPC at single-cell resolution, which provide insights into the mechanisms underlying NPC progression and the development of precise therapies for NPC.

Entities:  

Year:  2021        PMID: 33531485     DOI: 10.1038/s41467-021-21043-4

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  69 in total

1.  The genomic landscape of nasopharyngeal carcinoma.

Authors:  De-Chen Lin; Xuan Meng; Masaharu Hazawa; Yasunobu Nagata; Ana Maria Varela; Liang Xu; Yusuke Sato; Li-Zhen Liu; Ling-Wen Ding; Arjun Sharma; Boon Cher Goh; Soo Chin Lee; Bengt Fredrik Petersson; Feng Gang Yu; Paul Macary; Min Zin Oo; Chan Soh Ha; Henry Yang; Seishi Ogawa; Kwok Seng Loh; H Phillip Koeffler
Journal:  Nat Genet       Date:  2014-06-22       Impact factor: 38.330

Review 2.  Nasopharyngeal carcinoma.

Authors:  Yu-Pei Chen; Anthony T C Chan; Quynh-Thu Le; Pierre Blanchard; Ying Sun; Jun Ma
Journal:  Lancet       Date:  2019-06-06       Impact factor: 79.321

3.  Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

Authors:  Chiun Hsu; Se-Hoon Lee; Samuel Ejadi; Caroline Even; Roger B Cohen; Christophe Le Tourneau; Janice M Mehnert; Alain Algazi; Emilie M J van Brummelen; Sanatan Saraf; Pradeep Thanigaimani; Jonathan D Cheng; Aaron R Hansen
Journal:  J Clin Oncol       Date:  2017-08-24       Impact factor: 44.544

4.  Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.

Authors:  Anthony T C Chan; Mow-Ming Hsu; Boon C Goh; Edwin P Hui; Tsang-Wu Liu; Michael J Millward; Ruey-Long Hong; Jacqueline Whang-Peng; Brigette B Y Ma; Ka F To; Matthias Mueser; Nadia Amellal; Xiao Lin; Alex Y Chang
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

5.  Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.

Authors:  Wen-Fei Li; Nian-Yong Chen; Ning Zhang; Guo-Qing Hu; Fang-Yun Xie; Yan Sun; Xiao-Zhong Chen; Jin-Gao Li; Xiao-Dong Zhu; Chao-Su Hu; Xiang-Ying Xu; Yuan-Yuan Chen; Wei-Han Hu; Ling Guo; Hao-Yuan Mo; Lei Chen; Yan-Ping Mao; Rui Sun; Ping Ai; Shao-Bo Liang; Guo-Xian Long; Bao-Min Zheng; Xing-Lai Feng; Xiao-Chang Gong; Ling Li; Chun-Ying Shen; Jian-Yu Xu; Ying Guo; Yu-Ming Chen; Fan Zhang; Li Lin; Ling-Long Tang; Meng-Zhong Liu; Jun Ma; Ying Sun
Journal:  Int J Cancer       Date:  2019-01-24       Impact factor: 7.396

6.  Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma.

Authors:  Grace Tin-Yun Chung; Wilson Pak-Kin Lou; Chit Chow; Ka-Fai To; Kwong-Wai Choy; Alice Wan-Chi Leung; Carol Yuen-Kwan Tong; Jessie Wai-Fong Yuen; Chun-Wai Ko; Timothy Tak-Chun Yip; Pierre Busson; Kwok-Wai Lo
Journal:  J Pathol       Date:  2013-09-03       Impact factor: 7.996

7.  Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.

Authors:  Ying Sun; Wen-Fei Li; Nian-Yong Chen; Ning Zhang; Guo-Qing Hu; Fang-Yun Xie; Yan Sun; Xiao-Zhong Chen; Jin-Gao Li; Xiao-Dong Zhu; Chao-Su Hu; Xiang-Ying Xu; Yuan-Yuan Chen; Wei-Han Hu; Ling Guo; Hao-Yuan Mo; Lei Chen; Yan-Ping Mao; Rui Sun; Ping Ai; Shao-Bo Liang; Guo-Xian Long; Bao-Min Zheng; Xing-Lai Feng; Xiao-Chang Gong; Ling Li; Chun-Ying Shen; Jian-Yu Xu; Ying Guo; Yu-Ming Chen; Fan Zhang; Li Lin; Ling-Long Tang; Meng-Zhong Liu; Jun Ma
Journal:  Lancet Oncol       Date:  2016-09-27       Impact factor: 41.316

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations.

Authors:  Yvonne Y Li; Grace T Y Chung; Vivian W Y Lui; Ka-Fai To; Brigette B Y Ma; Chit Chow; John K S Woo; Kevin Y Yip; Jeongsun Seo; Edwin P Hui; Michael K F Mak; Maria Rusan; Nicole G Chau; Yvonne Y Y Or; Marcus H N Law; Peggy P Y Law; Zoey W Y Liu; Hoi-Lam Ngan; Pok-Man Hau; Krista R Verhoeft; Peony H Y Poon; Seong-Keun Yoo; Jong-Yeon Shin; Sau-Dan Lee; Samantha W M Lun; Lin Jia; Anthony W H Chan; Jason Y K Chan; Paul B S Lai; Choi-Yi Fung; Suet-Ting Hung; Lin Wang; Ann Margaret V Chang; Simion I Chiosea; Matthew L Hedberg; Sai-Wah Tsao; Andrew C van Hasselt; Anthony T C Chan; Jennifer R Grandis; Peter S Hammerman; Kwok-Wai Lo
Journal:  Nat Commun       Date:  2017-01-18       Impact factor: 14.919

10.  Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Authors:  Brigette B Y Ma; Wan-Teck Lim; Boon-Cher Goh; Edwin P Hui; Kwok-Wai Lo; Adam Pettinger; Nathan R Foster; Jonathan W Riess; Mark Agulnik; Alex Y C Chang; Akhil Chopra; Julie A Kish; Christine H Chung; Douglas R Adkins; Kevin J Cullen; Barbara J Gitlitz; Dean W Lim; Ka-Fai To; K C Allen Chan; Y M Dennis Lo; Ann D King; Charles Erlichman; Jun Yin; Brian A Costello; Anthony T C Chan
Journal:  J Clin Oncol       Date:  2018-03-27       Impact factor: 50.717

View more
  18 in total

Review 1.  Archetypes of checkpoint-responsive immunity.

Authors:  Kwok Im; Alexis J Combes; Matthew H Spitzer; Ansuman T Satpathy; Matthew F Krummel
Journal:  Trends Immunol       Date:  2021-10-09       Impact factor: 16.687

2.  Systematic evaluation of cell-type deconvolution pipelines for sequencing-based bulk DNA methylomes.

Authors:  Yunhee Jeong; Lisa Barros de Andrade E Sousa; Dominik Thalmeier; Reka Toth; Marlene Ganslmeier; Kersten Breuer; Christoph Plass; Pavlo Lutsik
Journal:  Brief Bioinform       Date:  2022-07-18       Impact factor: 13.994

Review 3.  Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.

Authors:  Xueyi Zheng; Yuhua Huang; Kai Li; Rongzhen Luo; Muyan Cai; Jingping Yun
Journal:  Viruses       Date:  2022-05-10       Impact factor: 5.818

Review 4.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Authors:  Liangliang Xu; Chang Zou; Shanshan Zhang; Timothy Shun Man Chu; Yan Zhang; Weiwei Chen; Caining Zhao; Li Yang; Zhiyuan Xu; Shaowei Dong; Hao Yu; Bo Li; Xinyuan Guan; Yuzhu Hou; Feng-Ming Kong
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

5.  Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC).

Authors:  Zhenzhen Hui; Jiali Zhang; Yulin Ren; Xiaoling Li; Cihui Yan; Wenwen Yu; Tao Wang; Shanshan Xiao; Yulong Chen; Ran Zhang; Feng Wei; Jian You; Xiubao Ren
Journal:  Cell Death Dis       Date:  2022-07-13       Impact factor: 9.685

Review 6.  Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers.

Authors:  Mingo M H Yung; Michelle K Y Siu; Hextan Y S Ngan; David W Chan; Karen K L Chan
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

7.  A primary nasopharyngeal three-dimensional air-liquid interface cell culture model of the pseudostratified epithelium reveals differential donor- and cell type-specific susceptibility to Epstein-Barr virus infection.

Authors:  Phillip Ziegler; Yarong Tian; Yulong Bai; Sanna Abrahamsson; Alan Bäckerholm; Alex S Reznik; Anthony Green; John A Moore; Stella E Lee; Michael M Myerburg; Hyun Jung Park; Ka-Wei Tang; Kathy Ho Yen Shair
Journal:  PLoS Pathog       Date:  2021-04-29       Impact factor: 6.823

8.  What role for AHR activation in IL4I1-mediated immunosuppression ?

Authors:  Flavia Castellano; Armelle Prevost-Blondel; José L Cohen; Valérie Molinier-Frenkel
Journal:  Oncoimmunology       Date:  2021-05-12       Impact factor: 8.110

9.  Dissecting the heterogeneity of the microenvironment in primary and recurrent nasopharyngeal carcinomas using single-cell RNA sequencing.

Authors:  Wen-Sa Peng; Xin Zhou; Wen-Bin Yan; Yu-Jiao Li; Cheng-Run Du; Xiao-Shen Wang; Chun-Ying Shen; Qi-Feng Wang; Hong-Mei Ying; Xue-Guan Lu; Ting-Ting Xu; Chao-Su Hu
Journal:  Oncoimmunology       Date:  2022-01-25       Impact factor: 8.110

Review 10.  Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies.

Authors:  Shuting Han; Joshua K Tay; Celestine Jia Ling Loh; Axel Jun Ming Chu; Joe Poh Sheng Yeong; Chwee Ming Lim; Han Chong Toh
Journal:  Front Immunol       Date:  2021-12-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.